Oncology Medical News about nilotinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
Cancer Chemotherapy and Pharmacology, 11/04/09

Radujkovic A et al. – The results demonstrate the efficacy of combination treatment regimens employing nilotinib and established chemotherapeutic agents in improving antileukemic effects in imatinib–sensitive and imatinib–resistant cells. This may be the foundation for further study on the potential of the applied combinations in a clinical setting.

<< Previous
Interim 18 F-fluorodeoxyglucose positron emission tomography in...

Next >>
Early detection of patients with poor risk diffuse large B-cell...

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Blood, 10/30/09 Relevance Score: 89%

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL + cell to Imatinib and Nilotinib
Leukemia and Lymphoma, 10/30/09 Relevance Score: 80%

Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Haematologica, 10/21/09 Relevance Score: 77%